Immune-mediated Thrombocytopenic Purpura
Conditions
Brief summary
The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.
Detailed description
Pediatric patients who received caplacizumab will be identified for enrollment in the chart review. The eligibility period starts on August 30, 2018 in the United Kingdom (UK) and France and February 6, 2019 for the United States (US). Data collection is fully retrospective and will be anchored to the patient's index event date. The index event date is defined as the date the patient initiated caplacizumab treatment. The study period begins at the index date and ends at the earliest date of chart abstraction initiation, 12 weeks after last dose of caplacizumab treatment, date of death, or loss to follow-upwhich ever comes first .
Interventions
DRUGCaplacizumab
as in real world practice
Sponsors
Sanofi
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patient's aged ≤18 years at start of caplacizumab treatment initiation * Patient has a diagnosis of iTTP documented in the medical records * Patient was treated with caplacizumab within the eligibility period
Exclusion criteria
* Patient declined use of data for study (where local regulations require patient notification of planned study) * Patient's medical chart is missing or not retrievable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse event | From index date up to 12 weeks after last dose of caplacizumab | including serious adverse events |
| Proportion of patients achieving clinical response | From index date up to 12 weeks after last dose of caplacizumab | defined as a normal platelet countand LDH \< 2 ULN for at least 48 hours following initial normalization or response of platelet count |
| Time to ADAMTS13 activity ≥ 20% | From index date up to 12 weeks after last dose of caplacizumab | where available and feasible |
| Platelet count response | From index date up to 12 weeks after last dose of caplacizumab | defined as time from caplacizumab initiation to initial platelet count ≥ 150×109/L with subsequent stop of daily plasma exchange (PE) within 5 days |
| Proportion of subjects with refractory iTTP | From index date up to 12 weeks after last dose of caplacizumab | defined as lack of doubling of platelet count after four days of caplacizumab treatment and a lactate dehydrogenase (LDH) level that remained above the upper limit of normal (ULN) range |
| Proportion of subjects with recurrent disease | From index date up to 12 weeks after last dose of caplacizumab | Proportion of subjects with iTTP exacerbation (defined as recurrence within 30 days after last PE) and Proportion of subjects with iTTP relapse (defined as recurrence more than 30 days after last PE) |
| Time to normalization of organ damage marker levels | From index date up to 12 weeks after last dose of caplacizumab | Defined asLDH ≤ 2 x ULN, Serum creatinine ≤ 1 x ULN, Cardiac troponin I ≤ 1 x ULN |
| Total duration of hospitalization stays | From index date up to 12 weeks after last dose of caplacizumab | — |
| Duration of intensive care unit (ICU) stay | From index date up to 12 weeks after last dose of caplacizumab | — |
| Duration of therapeutic PE | From index date up to 12 weeks after last dose of caplacizumab | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Types and duration of concomitant medications | From index date up to 12 weeks after last dose of caplacizumab | — |
| Treatment pattern of caplacizumab therapy | From index date up to 12 weeks after last dose of caplacizumab | Dosing and duration |
Countries
France
Outcome results
None listed